MIRA INFORM REPORT

Report Date :

07.08.2013

IDENTIFICATION DETAILS

Name :	EMAMI BIOTECH (SINGAPORE) PTE. LTD.
Registered Office :	7500A Beach Road #06-316 The Plaza Singapore 199591
Country :	Singapore
Financials (as on) :	March 2013
Date of Incorporation :	08.01.2009
Com. Reg. No.:	200900414E
Legal Form :	Limited Private Company
Line of Business :	General Wholesale Trade (Including General Importers and Exporters) Trade, Import, Export of Palm Oil and Other Byproducts of Palm.
No. of Employees :	Not Available

RATING & COMMENTS

MIRA’s Rating :

B

RATING		STATUS	PROPOSED CREDIT LINE
26-40	B	Capability to overcome financial difficulties seems comparatively below average.	Small

Status :	Moderate
Payment Behaviour :	Slow
Litigation :	Clear

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

ECGC Country Risk Classification List – March, 31^st, 2013

Country Name	Previous Rating (31.12.2012)	Current Rating (31.03.2013)
Singapore	A1	A1

Risk Category	ECGC Classification
Insignificant	A1
Low	A2
Moderate	B1
High	B2
Very High	C1
Restricted	C2
Off-credit	D

SINGAPORE - ECONOMIC OVERVIEW

Singapore has a highly developed and successful free-market economy. It enjoys a remarkably open and corruption-free environment, stable prices, and a per capita GDP higher than that of most developed countries. The economy depends heavily on exports, particularly in consumer electronics, information technology products, pharmaceuticals, and on a growing financial services sector. Real GDP growth averaged 8.6% between 2004 and 2007. The economy contracted 0.8% in 2009 as a result of the global financial crisis, but rebounded 14.8% in 2010, on the strength of renewed exports, before slowing to 5.2% in 2011 and 1.3% in 2012, largely a result of soft demand for exports during the second European recession. Over the longer term, the government hopes to establish a new growth path that focuses on raising productivity, which has sunk to an average of about 1.0% in the last decade. Singapore has attracted major investments in pharmaceuticals and medical technology production and will continue efforts to establish Singapore as Southeast Asia's financial and high-tech hub.

Source : CIA

Company Name:	Registered Number:
EMAMI BIOTECH (SINGAPORE) PTE. LTD.	200900414E

Date Incorporated:	Registered Office:	Telephone Number:
08/01/2009	7500A BEACH ROAD #06-316 THE PLAZA SINGAPORE 199591	NA
Age of Company:	Website:	Industry Type:
4	NA	COMMERCE-WHOLESALE

Risk Dashboard
Debts Turn Cash	Trend:	No. of Litigation Counts:
Company DTC:		NA
NA
The entity is paying current to the creditors		No. of Charges(s): 0
Industry DTC
23

Directors		Corporate Structure
Number of Current Directors	4	Holding Company:	EMAMI BIOTECH LTD
Number that are shareholders	1	No. of Subsidiaries & Associated Companies:	NA

EXECUTIVE SUMMARY

Company Name	:	EMAMI BIOTECH (SINGAPORE) PTE. LTD.
Registration No	:	200900414E
Date of Registration	:	08/01/2009
Former Name	:	NA
Date of Change of Name	:	NA
Type of Company	:	LIMITED PRIVATE COMPANY
Registered Address	:	7500A BEACH ROAD #06-316 THE PLAZA SINGAPORE 199591
Date of Change of Address	:	25/09/2012
Contact No.	:	NA
Fax No.	:	NA
Website	:	NA
Registered Activities	:	1. GENERAL WHOLESALE TRADE (INCLUDING GENERAL IMPORTERS AND EXPORTERS) TRADE, IMPORT, EXPORT OF PALM OIL AND OTHER BYPRODUCTS OF PALM 2. EXTENSION SERVICES (INCLUDING AGRICULTURAL RESEARCH AND EXPERIMENTATION)
Issued Ordinary Capital*	:	$447,200.00 SINGAPORE, DOLLARS ,NO. OF SHARE : 447,200
Issued Preference Capital	:	NA
Paid-Up Ordinary Capital	:	$447,200.00 SINGAPORE, DOLLARS
Paid-Up Preference Capital	:	NA
* Number of Shares includes number of Issued Treasury Shares
Issued Treasury Capital	:	NA
Paid-Up Treasury Capital	:	NA
No. of Local Subsidiaries	:	NA
No. of Local Associates	:	NA
Auditor	:	S. RENGANATHAN & CO.
Bankers / Financiers	:	NA
Turnover	:	SGD - SIN 12,381,555.00 (FY2013)
Net Worth	:	SGD - SIN 426,447.00 (FY2013)
No. of Bank Charges	:	NA
No. of Litigation Suits	:	NA
S1000 / SME 1000 / FG50 Ranking	:	No found for SINGAPORE 1000 and SME 1000
Compounded Annual Growth Rate (CAGR)	:	21.19% (3 years)

SHAREHOLDER DETAILS

NAME	:	EMAMI BIOTECH LTD
SHAREHOLDER ID	:	T09UF0071B
NATIONALITY	:	NA
ADDRESS	:	687 ANANDAPUR E.M. BYPASS KOLKATTA 700107 INDIA
NO. OF ORD SHARES	:	447,200
% OF SHAREHOLDING	:	100%
CURRENCY	:	SINGAPORE, DOLLARS

OFFICER DETAILS

NAME	:	SWAPAN KUMAR MONDAL
ADDRESS	:	3, BAISHNAB GHATA PATULI GARIA KOLKATA, 700094, INDIA
POSITION	:	DIRECTOR
DATE OF APPT	:	08/01/2009
NATIONALITY	:	INDIAN
I/C PASSPORT	:	F9044860
NAME	:	YOGESH GOENKA
ADDRESS	:	7500A BEACH ROAD #06-316 THE PLAZA SINGAPORE 199591
POSITION	:	DIRECTOR
DATE OF APPT	:	22/02/2013
NATIONALITY	:	INDIAN
I/C PASSPORT	:	G6454157P
NAME	:	TIBREWAL RAJIV KUMAR
ADDRESS	:	19 NAND LAL MITRA LANE PO-SALKIA, HOWRAH - 711106 WEST BENGAL INDIA
POSITION	:	DIRECTOR
DATE OF APPT	:	22/02/2013
NATIONALITY	:	INDIAN
I/C PASSPORT	:	H2975051
NAME	:	ASHOK KUMAR AGRAWAL
ADDRESS	:	37 SIMEI RISE #01-13 SAVANNAH CONDOPARK SINGAPORE 528782
POSITION	:	DIRECTOR
DATE OF APPT	:	08/01/2009
NATIONALITY	:	SINGAPORE CITIZEN
I/C PASSPORT	:	S2653855F
NAME	:	RAMAKRISHNAN SRIVIDYA
ADDRESS	:	10 CHAI CHEE ROAD #03-07 SINGAPORE 467010
POSITION	:	SECRETARY
DATE OF APPT	:	31/05/2010
NATIONALITY	:	SINGAPORE P.R.
I/C PASSPORT	:	S7367371B

KEY PERSONNEL PROFILE

Name:	SWAPAN KUMAR MONDAL
NRIC Number:	F9044860
Available Address:	3, BAISHNAB GHATA PATULI GARIA KOLKATA, 700094, INDIA

Current Business Interest

No.	Name	Position	Appt Date	#of Share	%
1	EMAMI BIOTECH (SINGAPORE) PTE. LTD.	DIRECTOR	08/01/2009	-	-

Previous Business

No.	Name	Status	Position	Appt Date	Last Known Inactive Date
No Trace

Bankruptcy Record

Case No.	Year	Date of Filing	Petitioner Name	Amount
No Trace

Litigation Search – Writ of Summons

Court	Case No.	Transfer	Year	Date of Filing	Amount	Cause Category
No Trace

SUBSIDIARIES AND ASSOCIATE COMPANIES

Company	Shareholdings (%)
NA

BANKERS/ FINANCIERS

Subject enjoys a normal banking routine with its bankers. To date, there are no bank charges registered against Subject by its bankers.

LITIGATION

Clear

COMPLIANCE

Date of Last AGM	:	30/05/2013
Date of Last AR	:	22/06/2013
Date of A/C Laid At Last AGM	:	31/03/2013

FINANCIAL HIGHLIGHTS

Financial Figures	Company
	MAR 2013	% Change	MAR 2012
Currency	SGD - SIN		SGD - SIN
Profit and Loss Key Figures
Turnover	12,381,555	7.83	11,482,304
Profit/(Loss) Before Tax	18,431	46.10	12,615
Profit After Tax attributable to Shareholders	18,431	46.10	12,615
Balance Sheet Key Figures
Total Assets	437,019	3.49	422,263
Current Assets	437,019	3.49	422,263
Non Current Assets	0	NA	0
Total Liabilities	10,572	-5.93	11,238
Current Liabilities	10,572	-5.93	11,238
Non Current Liabilities	0	NA	0
Shareholders' Funds	426,447	3.75	411,025
Share Capital	427,797	-0.73	430,952
Total Reserves	(1,350)	NA	(19,927)

FINANCIAL RATIOS

	Company
	MAR 2013	MAR 2012
Growth %
Year-on-Year Growth	7.83	40,637.61
Profitability
Profit Margin (%)	0.15	0.11
Return on Equity (%)	4.32	3.07
Return on Assets (%)	4.22	2.99
Leverage
Total Debt/Equity (Times)	0.02	0.03
Current Debt/Equity (Times)	0.02	0.03
Long Term Debt To Equity (Times)	0.00	0.00
Total Asset To Total Equity (Times)	1.02	1.03
Asset Management
Total Assets Turnover (Times)	28.33	27.19
Fixed Assets Turnover (Times)	0.00	0.00
Liquidity
Current Ratio (Times)	41.34	37.57

FINANCIAL COMMENTARY

Compound Annual Growth Rate

The company's CAGR is 21.19% (3 years).

CAGR is the year-over-year growth rate of a company over a specified period. Instead of looking at the average growth rate, CAGR allow users to look at the annualized growth rate of a company over a given period, a more indicative measure of growth of a company’s performance over a given period.

Profitability

The company yielded a rate of net profit on sales of 0.15 per cent in FY13 (FY12: 0.11 per cent). The company is now able to book in SGD - SIN 0.00 of profit for every SGD - SIN of sales in FY13, as compared with SGD - SIN 0.00 a year ago.

Liquidity

Current ratio stood at 41.34 times in FY13 (FY12: 37.57 times). This means that the company has SGD - SIN 41.34 of current assets for every SGD - SIN of current liability incurred.

A minimum figure of 1.0 would be considered the lowest limit that this figure should reach. Any business that has a current ratio near 1.0 may be heading for liquidity problems, and would need to be closely monitored. A figure greater than 2.0 would be more desirable, to act as a buffer against any short-term liquidity problems, and give creditors/bank managers a degree of comfort when granting credit/finance.

FINANCIAL COMMENTARY

Leverage

Total debt-to-equity ratio notched 0.02 times in FY13, compared with 0.03 times in FY12. This means that the company requires additional external financing of SGD - SIN 0.02 for every SGD - SIN injected into its operations.

Generally, a total debt-to-equity ratio of less than 0.5 times is preferred. The ratio measures the proportion of the company's reliance on external debt for financing, relative to the shareholder's fund. A lower ratio would imply a greater financial safety and operating freedom for the company.

Efficiency Ratio

Return on equity was 4.32 per cent for Subject in the current financial period, as compared to 3.07 per cent a year ago. The return on equity measures the return earned on the owner's investment. Generally, the higher this return, the better off the owner.

Return on assets stood at 4.22 per cent (FY12: 2.99 per cent). The return on asset measures the overall effectiveness of management in generating profit with its available assets.

Total assets turnover ratio logged at 28.33 times in FY13 (FY12: 27.19 times). This ratio measures the company's ability to make productive use of its total assets to generate sales which reflects the efficiency of the management in utilising its resources.

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	Rs.61.54
UK Pound	1	Rs.94.37
Euro	1	Rs.81.57

ss

INFORMATION DETAILS

Report Prepared by :

SMN

RATING EXPLANATIONS

RATING		STATUS	PROPOSED CREDIT LINE
>86	Aaa	Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums	Unlimited
71-85	Aa	Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums	Large
56-70	A	Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums	Fairly Large
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory
26-40	B	Capability to overcome financial difficulties seems comparatively below average.	Small
11-25	Ca	Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity	Limited with full security
<10	C	Absolute credit risk exists. Caution needed to be exercised	Credit not recommended
----	NB	New Business	----

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

Financial condition (40%) Ownership background (20%) Payment record (10%)

Credit history (10%) Market trend (10%) Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.